Phase IIb study investigating the efficacy of GRC 6211 for the treatment of neuropathic pain and osteoarthritis
Latest Information Update: 12 Nov 2008
At a glance
- Drugs GRC 6211 (Primary)
- Indications Musculoskeletal pain; Neuropathic pain; Osteoarthritis
- Focus Therapeutic Use
- Sponsors Glenmark Pharmaceuticals S.A.
- 24 Oct 2008 Clinical development of GRC 6211 in osteoarthritis has been suspended.
- 05 Jun 2007 New trial record.